This summary shows the updated results of an ongoing research study called CROWN that was published in The Lancet Respiratory Medicine in December 2022. In the CROWN study, researchers looked at the effects of two study medicines called lorlatinib and crizotinib. The study included people with advanced non-small-cell lung cancer (NSCLC) that had not been treated previously. All people in the study had cancer cells with changes (known as alterations) in a gene called anaplastic lymphoma kinase, or ALK. This ALK gene is involved in cancer growth. In this updated study, researchers looked at the continued benefit in people who took lorlatinib compared with people who took crizotinib after 3 years.

This Plain Language Summary of Publication from Future Oncology summarises the updated results of an ongoing research study called CROWN. The  CROWN study looked at the effects of two medicines called lorlatinib with crizotinib which they used to treat people with advanced non-small-cell lung cancer (NSCLC). The people in the study had cancer cells with changes in a gene called anaplastic lymphoma kinase, or ALK. This ALK gene is involved in cancer growth.

Read the full article here.

The original article on which this summary is based was published in the The Lancet Respiratory Medicine. The original article is called ‘Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study’. You can read it here.